PBKM gets FDA approval to supply to medical centres in US
…be delivered to transplant centres across the US and will be used primarily in the treatment of leukaemia and also autoimmune disorders, said CEO Jakub Baran. In 2016 PBKM supplied blood and tissue for the treatment of more than 170 haematological patients from approximately 20 countries.
Sign up now to open the entire news item.You are allowed to open only one news item from PMR websites.
(to send requested information)
(required for new e-mails only)